Frequently Used Tools:

• Webmail  | 
• Tmail  | 
• Online@UT  | 
• A-Z Index

Search The University of Tennessee:

College of Veterinary Medicine »

• Academic Departments
  • Comparative Medicine
  • Pathobiology
  • Large Animal Clinical Sciences
  • Small Animal Clinical Sciences

Faculty

Education

• 1979, DVM equivalent (BVM), Veterinary Medicine, National Chung-Hsing University, Taiwan, R.O.C.
• 1984, MS, Veterinary Viral Infectious Diseases, Auburn University, School of Veterinary Medicine, Auburn, Alabama
• 1990, Ph.D. Molecular Biology/Oncogene, University of Virginia Cancer Center, Charlottesville, Virginia

Training

• 1992 Postdoctoral Fellow, Biochemistry and Cellular Biology, Harvard University, Cambridge, MA
• 1994 Postdoctoral Research Associate, Intracellular Signaling Pathways, Harvard University, Cambridge, MA

Teaching

• Postdoctoral research fellow training
• Graduate student training
• Graduate Course: Mechanisms of Disease
• Graduate Course: Disorders of the Endocrine System
• Graduate Course: Cancer Cell Biology
• Undergraduate Course: Cancer Biology

Clinical Interests

• Clinical studies for anticancer agents and detection

Research Interests

My research interests are to pursue novel molecules functioning in a quiescent state of normal cells and in apoptosis of malignantly transformed cells and to build translational research as a bridge from basic research to clinical research and applications for anticancer therapeutics and prevention. The goal of my basic research is to have a better understanding of the control of human cancers through exploration of novel signaling pathways for regulating cellular transformation, quiescence, and apoptosis. The approach of my translational research is to build preclinical models that reflect the molecular basis of cancer etiology and progression and for studies of tumor biology and etiology. Through molecular classification of oncogene- or carcinogen-induced human cancer cells, the genetic and molecular changes will be utilized as elements to constitute unique, identifiable characteristics of signatures of precancerous and cancerous cells at all stages of cancer development. Based on the molecular signature of cancerous cells, we will be able to determine the stage of cancers and identify molecular targets for choosing agents that prevent cancer by interfering with the biological processes underlying cancer development. Through collaborations we expect to establish research programs with multi-disciplines to link basic molecular and cellular research to clinical studies that will benefit our society for anticancer prevention and treatment.

Current Projects

• Identifying the role of a new family of protein kinase Krs-1 (Kinase Responsive to Stress-1) and its derived kinase QIK (Quiescence-Induced Kinase), in modulating signaling pathways for cell quiescence and apoptosis.
• Developing a precancerous human breast carcinogenesis cellular model with biological amd molecular target endpoints for identifying preventive agents.
• International Multi-Task Cooperative and Exchange Program, Association of American Veterinary Medical Colleges, Global Initiatives in Veterinary Education (GIVE) Program

Professional Societies

• American Association for the Advancement of Science
• American Association for Cancer Research
• Chinese-American Academic and Professional Association in Southeastern United States
• International Affairs Committee, Association of American Veterinary Medicine Colleges

Publications

• Choudhary, S. and Wang, H-C.R. Pro-apoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells. Molecular Cancer Therapeutics 6:1099-1111, 2007.
• Choudhary, S. and Wang, H-C.R. Pro-apoptotic activity of oncogenic H-Ras for histone deacetylase inhibitor to induce apoptosis of human cancer HT29 cells. Journal of Cancer Research and Clinical Oncology 133:725-739, 2007.
• Siriwardhana N. and Wang, H-C.R. Precancerous Carcinogenesis of Human Breast Epithelial Cells by Chronic Exposure to Benzo[a]pyrene. Molecular Carcinogenesis 5:338-348, 2008.
  (This report is recognized as the May 2008 feature cover article in Molecular Carcinogenesis)
• Siriwardhana, N., Choudhary, S., and Wang, H-C.R. Precancerous model of human breast epithelial cells induced by the tobacco-specific carcinogen NNK for prevention. Breast Cancer Research and Treatment 109:427-441, 2008.
• Song, P., Wei, J., and Wang, H-C.R. 2005. Distinct roles of the ERK pathway in modulating apoptosis of Ras-transformed and non-transformed cells induced by anticancer agent FR901228. FEBS Letters:579:90-94
• Song, P., Wei, J., Plummer III, H., and Wang, H-C.R. 2004. Potentiated caspase-3 in ras-transformed 10T1/2 cells. Biochemical and Biophysical Research Communications 322:557-564.
• Song, P. and Wang, H-C.R. 2004. Efficient Identification of TetR-Expressed Cell Lines for Tetracycline-Regulated Gene Expression. Electronic Journal of Biotechnology 7(2): 195-198.
• Wang, H-C.R. 2003. The role of Krs1 in cell cycle arrest. Drug News and Perspectives 16(10), 663-668.
• Wang, H-C.R. and Parsons, J.T. 1989. Deletions and insertions within an aminoterminal domain of pp60^v-src inactivate transformation and modulate membrane stability. Journal of Virology63:291-302.
• Reynolds, A.B., Kanner, S.B., Wang, H-C.R., and Parsons, J.T. 1990. Stable association of activated pp60^src with two tyrosine-phosphorylated cellular proteins. Molecular and CellBiology 9:3951-3958.
• Bouton, A.H., Kanner,S.B., Vines, R.R., Wang, H-C.R., Gibbs, J.B., and Parsons,J.T. 1991. Transformation by pp60^src or stimulation of cells with epidermal growth factor induces the stable association of tyrosine phosphorylated cellular proteins with GTPase activating protein. Molecular and Cell Biology 11:945-953.
• Kanner, S.B., Reynolds,A.B., Wang, H-C.R., Vines, R.R., and Parsons, J.T. 1991. The SH2 and SH3 domains of pp60^src direct stable association with tyrosine-phosphorylated proteins p130 and p110. EMBO. Journal 10:1689-98.
• Wang, H-C.R. and Erikson, R.L. 1992. Activation of protein serine/threonine kinasesp42, p63 and p87 in Rous sarcoma virus-transformed cells: Signal transduction/Transformation-dependent MBP kinases. Molecular Biology of Cell 3:1329-1337.
• Wang, H-C.R. 1996. Induction of down-regulation of the kinase activities of Mek,p42^Erk, p90^RSK, and p63^SAMK in chicken embryo fibroblast at the late stage of src-induced cellular transformation. Journal of Cellular Physiology168:87-96.
• Taylor, L., Wang, H-C.R., and Erikson, R.L. 1996. Newly identified stress-responsive protein kinases KRS-1 and KRS-2. Proceedings of the National Academy of Sciences USA 93:10099-10104.
• Shidaifat, F., Canatan, H., Kulp, S., Sugimoto, Y., Zhang, Y., Brueggemeier, R.W., Somers,W.J., Chang, W.Y., Wang, H-C.R., and Lin, Y.C. 1997. Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle. Anticancer Research 17:1003-1010.
• Mehta, V., Connors, L., Wang, H-C.R., and Chiu, I.M. 1998. Fibroblast variants nonresponsive to FGF-1 are defective in its nuclear translocation. Journal of Biological Chemistry 273:4197-4205.
• Rajgolikar, G, Chan,K.K., and Wang, H-C.R. 1998. Effects of a novel antitumor depsipeptide FR901288 on human breast cancer cells. Breast Cancer Research and Treatment 51:29-38.
• Wang, H-C.R. 1999. FR901228, Antineoplastic antibiotic. Drug of the Future 24:1184-1188.
• Wang, H-C.R. 2000. Recovery of protein kinases from renatured SDS-polyacrylamide gels for biochemical studies. BioTechniques 28:232-238.
• Wang, H-C.R. and Fecteau, K.A. 2000. Detection of a novel quiescence-dependent protein kinase. Journal of Biological Chemistry 275:25850-25857.
• Fecteau, KA., Mei, J., and Wang, H-C.R. 2002. Differential modulation of signaling pathways and apoptosis of ras-transformed 10T1/2 cells by the depsipeptide FR901228. Journal of Pharmacology and Experimental Therapeutics, 300:890-899.
• Mei, J., Hu, H.,McEntee, M., Plummer III, H., Song, P., and Wang, H-C.R. 2003 Transformation of noncancerous human breast epithelial cell MCF10A induced by the tobacco-specific carcinogen NNK. Breast Cancer Research and Treatment , 79:95-105.